Investor's Business Daily on MSN28m
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected HitchHims stock reversed lower Wednesday as analysts laid out low expectations for Him & Hers' branded tirzepatide.
The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback